Please Wait.....
Report
North America Alzheimer'S Disease Therapeutics & Diagnostics Market Forecast 2024-2032
Market Report I 2024-11-27 I 145 Pages I Inkwood Research
KEY FINDINGS
The North America Alzheimer's disease therapeutics & diagnostics market is estimated to develop with a CAGR of 5.60% over the forecast period 2024-2032. The market was valued at $2941.34 million in 2023 and is expected to reach a revenue of $4825.00 million by 2032.
MARKET INSIGHTS
The North America Alzheimer's disease therapeutics & diagnostics market is expanding due to several key factors. The increase in Alzheimer's disease cases, coupled with advancements in diagnostic technologies, is driving market growth. As the elderly population continues to expand, there is a rising demand for more effective diagnostic tools and therapeutics. Moreover, the growth in the number of drugs under development, including those targeting the underlying causes of Alzheimer's, is enhancing treatment options and fueling market expansion. These factors collectively contribute to a more dynamic and rapidly evolving Alzheimer's disease market in North America.
REGIONAL ANALYSIS
The North America Alzheimer's disease therapeutics & diagnostics market growth evaluation entails the assessment of the United States and Canada.
The US is home to several leading pharmaceutical companies and research institutions focused on developing innovative therapies and diagnostic tools. Advancements in early detection techniques, such as biomarker testing and imaging technologies, are improving the ability to diagnose Alzheimer's at earlier stages, which, in turn, boosts the demand for therapeutics. Additionally, increased funding for Alzheimer's research and public health initiatives is supporting market growth and enhancing treatment options for patients.
In Canada, the Alzheimer's disease therapeutics & diagnostics market is experiencing steady growth as the elderly population expands and awareness of Alzheimer's care improves. The Canadian healthcare system plays a pivotal role in ensuring broad access to emerging diagnostic tools and treatment options, contributing to the market's development. Canadian research institutions are also at the forefront of innovative studies, focusing on novel drug candidates and non-invasive diagnostic methods. As both countries continue to address the challenges posed by an aging population, the Alzheimer's disease therapeutics & diagnostics market in North America is poised for continued expansion.
SEGMENTATION ANALYSIS
The North America Alzheimer's disease therapeutics & diagnostics market segmentation includes the market by product. The product segment is further differentiated into therapeutics (including cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutics) as well as diagnostics (including brain imaging, CSF test for Alzheimer's disease, and other diagnostics).
Cholinesterase inhibitors are a primary class of therapeutics used in the treatment of Alzheimer's disease, aimed at alleviating symptoms by increasing the levels of acetylcholine. Further, this neurotransmitter is often depleted in patients with Alzheimer's. Acetylcholine plays a crucial role in memory and learning processes, and its reduction is associated with cognitive decline in Alzheimer's disease. Cholinesterase inhibitors work by blocking the enzyme acetylcholinesterase, which breaks down acetylcholine, thereby enhancing its availability and improving communication between nerve cells. Drugs like donepezil, rivastigmine, and galantamine fall under this category and are commonly prescribed to patients with mild to moderate Alzheimer's disease to help manage cognitive symptoms and slow disease progression.
Although cholinesterase inhibitors do not cure Alzheimer's, they are effective in improving symptoms or slowing their progression in some individuals. These medications may also help in stabilizing cognitive function and enhancing the ability to perform daily activities. However, their effectiveness varies among patients, and they can be associated with side effects such as nausea, diarrhea, insomnia, and muscle cramps. As part of a comprehensive Alzheimer's treatment plan, cholinesterase inhibitors are often used in combination with other therapies, such as NMDA receptor antagonists, to address a broader range of symptoms and enhance patient outcomes.
COMPETITIVE INSIGHTS
Some of the leading players in the North America Alzheimer's disease therapeutics & diagnostics market include Baxter International Inc, Allergan PLC (acquired by AbbVie), Biogen Inc, Cognoptix Inc, etc.
Baxter International Inc, headquartered in Deerfield, Illinois, United States, is a global healthcare company specializing in medical devices, pharmaceuticals, and biotechnology. Founded in 1931, it focuses on critical care therapies, including renal and hospital care. The company operates in over 100 countries and is known for its innovative healthcare solutions. Baxter is committed to improving patient outcomes through advanced medical technologies and sustainable practices.
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON THE NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. GROWING R&D INVESTMENT IN THE BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.5.2. INCREASING DEMAND FOR THE PERSONALIZED MEDICINES
3. MARKET DYNAMICS
3.1. PARENT MARKET ANALYSIS
3.2. KEY DRIVERS
3.2.1. INCREASE IN ALZHEIMER'S DISEASE CASES
3.2.2. ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES
3.2.3. GROWTH IN THE NUMBER OF DRUGS UNDER DEVELOPMENT
3.2.4. EXPANSION OF THE ELDERLY POPULATION
3.3. KEY RESTRAINTS
3.3.1. LIMITED AVAILABILITY OF SURROGATE MARKERS
3.3.2. LATE-STAGE DRUG FAILURES
3.3.3. STRICT GOVERNMENT REGULATIONS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. ADVANCEMENTS IN IN-VITRO DIAGNOSTIC TECHNIQUES
4.1.2. USAGE OF COMPUTED TOMOGRAPHY IN THE DIAGNOSTICS OF ALZHEIMER'S DISEASE
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR NORTH AMERICA
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
4.6.1. R&D
4.6.2. RAW MATERIAL
4.6.3. MANUFACTURING
4.6.4. WHOLESALERS/DISTRIBUTORS/RETAILERS
4.6.5. END-USER
4.7. KEY BUYING CRITERIA
4.7.1. PRICE
4.7.2. EFFICIENCY
4.7.3. SAFETY
4.8. ETYMOLOGY OF THE NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
4.9. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
5. MARKET BY PRODUCT
5.1. THERAPEUTICS
5.1.1. CHOLINESTERASE INHIBITORS
5.1.2. NMDA RECEPTOR ANTAGONISTS
5.1.3. OTHER THERAPEUTICS
5.2. DIAGNOSTICS
5.2.1. BRAIN IMAGING
5.2.2. CSF TEST FOR ALZHEIMER'S DISEASE
5.2.3. OTHER DIAGNOSTICS
6. GEOGRAPHICAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. MARKET SIZE & ESTIMATES
6.1.2. NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET DRIVERS
6.1.3. NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET CHALLENGES
6.1.4. NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET REGULATORY FRAMEWORK
6.1.5. KEY PLAYERS IN NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
6.1.6. COUNTRY ANALYSIS
6.1.6.1. UNITED STATES
6.1.6.1.1. UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
6.1.6.2. CANADA
6.1.6.2.1. CANADA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
7. COMPETITIVE LANDSCAPE
7.1. KEY STRATEGIC DEVELOPMENTS
7.1.1. MERGERS & ACQUISITIONS
7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
7.1.3. PARTNERSHIPS & AGREEMENTS
7.1.4. BUSINESS EXPANSIONS & DIVESTITURES
7.2. COMPANY PROFILES
7.2.1. BAXTER INTERNATIONAL INC
7.2.1.1. COMPANY OVERVIEW
7.2.1.2. PRODUCT LIST
7.2.1.3. STRENGTHS & CHALLENGES
7.2.2. ALLERGAN PLC (ACQUIRED BY ABBVIE)
7.2.2.1. COMPANY OVERVIEW
7.2.2.2. PRODUCT LIST
7.2.2.3. STRENGTHS & CHALLENGES
7.2.3. BIOGEN INC
7.2.3.1. COMPANY OVERVIEW
7.2.3.2. PRODUCT LIST
7.2.3.3. STRENGTHS & CHALLENGES
7.2.4. COGNOPTIX INC
7.2.4.1. COMPANY OVERVIEW
7.2.4.2. PRODUCT LIST
7.2.4.3. STRENGTHS & CHALLENGES
7.2.5. ELI LILLY AND COMPANY
7.2.5.1. COMPANY OVERVIEW
7.2.5.2. PRODUCT LIST
7.2.5.3. STRENGTHS & CHALLENGES
7.2.6. F HOFFMANN-LA ROCHE
7.2.6.1. COMPANY OVERVIEW
7.2.6.2. PRODUCT LIST
7.2.6.3. STRENGTHS & CHALLENGES
7.2.7. LUPIN LIMITED
7.2.7.1. COMPANY OVERVIEW
7.2.7.2. PRODUCTS LIST
7.2.7.3. STRENGTHS & CHALLENGES
7.2.8. MERCK & CO INC
7.2.8.1. COMPANY OVERVIEW
7.2.8.2. PRODUCT LIST
7.2.8.3. STRENGTHS & CHALLENGES
7.2.9. NOVARTIS AG
7.2.9.1. COMPANY OVERVIEW
7.2.9.2. PRODUCTS LIST
7.2.9.3. STRENGTHS & CHALLENGES
7.2.10. SUN PHARMACEUTICALS INDUSTRIES LTD
7.2.10.1. COMPANY OVERVIEW
7.2.10.2. PRODUCT LIST
7.2.10.3. STRENGTHS & CHALLENGES
7.2.11. PFIZER INC
7.2.11.1. COMPANY OVERVIEW
7.2.11.2. PRODUCTS LIST
7.2.11.3. STRENGTHS & CHALLENGES
7.2.12. EISAI CO LTD
7.2.12.1. COMPANY OVERVIEW
7.2.12.2. PRODUCT LIST
7.2.12.3. STRENGTHS & CHALLENGES
7.2.13. JOHNSON & JOHNSON
7.2.13.1. COMPANY OVERVIEW
7.2.13.2. PRODUCT LIST
7.2.13.3. STRENGTHS & CHALLENGES
7.2.14. GE HEALTHCARE
7.2.14.1. COMPANY OVERVIEW
7.2.14.2. PRODUCT LIST
7.2.14.3. STRENGTHS & CHALLENGES
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS
TABLE 2: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET REGULATORY FRAMEWORK
TABLE 3: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 4: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY PRODUCT, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 5: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 6: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 7: KEY PLAYERS OPERATING IN NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 8: LIST OF MERGERS & ACQUISITIONS
TABLE 9: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 10: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 11: LIST OF BUSINESS EXPANSIONS & DIVESTITURES
LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR NORTH AMERICA
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: KEY BUYING CRITERIA
FIGURE 8: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2023
FIGURE 9: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2024-2032 (IN $ MILLION)
FIGURE 10: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS, IN 2023
FIGURE 11: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY CHOLINESTERASE INHIBITORS, 2024-2032 (IN $ MILLION)
FIGURE 12: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY NMDA RECEPTOR ANTAGONISTS, 2024-2032 (IN $ MILLION)
FIGURE 13: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY OTHER THERAPEUTICS, 2024-2032 (IN $ MILLION)
FIGURE 14: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2024-2032 (IN $ MILLION)
FIGURE 15: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2023
FIGURE 16: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY BRAIN IMAGING, 2024-2032 (IN $ MILLION)
FIGURE 17: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY CSF TEST FOR ALZHEIMER'S DISEASE, 2024-2032 (IN $ MILLION)
FIGURE 18: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2024-2032 (IN $ MILLION)
FIGURE 19: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
FIGURE 20: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2024-2032 (IN $ MILLION)
FIGURE 21: CANADA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2024-2032 (IN $ MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security